242 related articles for article (PubMed ID: 8362600)
81. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group.
Rogers E; Bredin H; Butler M; Corcoran M; Egan E; Fennelly J; Grainger R; Aleer SM; Dermott TM; Mullins G; Tanner A; Twomey A; Thornhill J
Eur Urol; 2000 Mar; 37(3):261-6. PubMed ID: 10720849
[TBL] [Abstract][Full Text] [Related]
82. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
West WH; Tauer KW; Yannelli JR; Marshall GD; Orr DW; Thurman GB; Oldham RK
N Engl J Med; 1987 Apr; 316(15):898-905. PubMed ID: 3493433
[TBL] [Abstract][Full Text] [Related]
83. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients.
Maddrey WC
Semin Liver Dis; 1999; 19 Suppl 1():67-75. PubMed ID: 10349694
[TBL] [Abstract][Full Text] [Related]
84. Immunomodulatory effects of interleukin-2 and interleukin-4 in patients with malignancy.
Olencki T; Finke J; Tubbs R; Tuason L; Greene T; McLain D; Swanson SJ; Herzog P; Stanley J; Edinger M; Budd GT; Bukowski RM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):69-80. PubMed ID: 8859726
[TBL] [Abstract][Full Text] [Related]
85. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
86. The role of interferon alfa in the treatment of metastatic melanoma.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S24-31. PubMed ID: 9122731
[TBL] [Abstract][Full Text] [Related]
87. A phase I study of subcutaneous recombinant interleukin-2 in patients with advanced HIV disease while on zidovudine.
McMahon DK; Armstrong JA; Huang XL; Rinaldo CR; Gupta P; Whiteside TL; Pazin GJ; Tripoli C; Ho M
AIDS; 1994 Jan; 8(1):59-66. PubMed ID: 8011237
[TBL] [Abstract][Full Text] [Related]
88. Separate and combined effects of recombinant interleukin-1 alpha and gamma interferon on antibacterial resistance.
Kurtz RS; Young KM; Czuprynski CJ
Infect Immun; 1989 Feb; 57(2):553-8. PubMed ID: 2492263
[TBL] [Abstract][Full Text] [Related]
89. Phase I trial of continuous infusion interleukin-2 and doxorubicin in patients with refractory malignancies.
Bukowski RM; Sergi JS; Budd GT; Murthy S; Tubbs R; Gibson V; Bauer L; Stanley J; Gautam S; Finke J
J Immunother (1991); 1991 Dec; 10(6):432-9. PubMed ID: 1768677
[TBL] [Abstract][Full Text] [Related]
90. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.
Nagler A; Ackerstein A; Or R; Naparstek E; Slavin S
Blood; 1997 Jun; 89(11):3951-9. PubMed ID: 9166832
[TBL] [Abstract][Full Text] [Related]
91. A phase I study of interferon-alpha 2b in combination with interleukin-2 in patients with human immunodeficiency virus infection.
Schnittman SM; Vogel S; Baseler M; Lane HC; Davey RT
J Infect Dis; 1994 May; 169(5):981-9. PubMed ID: 7909550
[TBL] [Abstract][Full Text] [Related]
92. Phase I study of low-dose cyclophosphamide and recombinant interleukin-2 for the treatment of advanced cancer.
Verdi CJ; Taylor CW; Croghan MK; Dalke P; Meyskens FL; Hersh EM
J Immunother (1991); 1992 May; 11(4):286-91. PubMed ID: 1599914
[TBL] [Abstract][Full Text] [Related]
93. Combination therapy of colon carcinoma 26 in mice with recombinant human interleukin-2 and interferon-alpha A/D: occurrence of large granular cells in the tumor.
Sakura Y; Ootsu K; Shino A
Jpn J Cancer Res; 1989 Sep; 80(9):895-903. PubMed ID: 2513305
[TBL] [Abstract][Full Text] [Related]
94. Studies of interferons in the therapy of melanoma.
Kirkwood JM
Semin Oncol; 1991 Oct; 18(5 Suppl 7):83-90. PubMed ID: 1948134
[TBL] [Abstract][Full Text] [Related]
95. Phase I/II study of recombinant interferon alpha and gamma in advanced progressive renal-cell carcinoma.
de Mulder PH; Debruyne FM; Franssen MP; Geboers AD; Strijk S; Reintjes AG; Doesburg WH; Damsma O
Cancer Immunol Immunother; 1990; 31(5):321-4. PubMed ID: 2115817
[TBL] [Abstract][Full Text] [Related]
96. Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials.
Mahmoudpour SH; Jankowski M; Valerio L; Becker C; Espinola-Klein C; Konstantinides S; Quitzau K; Barco S
Sci Rep; 2019 May; 9(1):7145. PubMed ID: 31073219
[TBL] [Abstract][Full Text] [Related]
97. Phase I study of recombinant human interleukin-2 for pediatric malignancies: feasibility of outpatient therapy. A Pediatric Oncology Group Study.
Pais RC; Abdel-Mageed A; Ghim TT; Ode D; Melendez E; Kim HS; Findley H; Ragab AH
J Immunother (1991); 1992 Aug; 12(2):138-46. PubMed ID: 1504055
[TBL] [Abstract][Full Text] [Related]
98. Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer.
Viens P; Blaise D; Stoppa AM; Brandely M; Baume D; Olive D; Resbeut M; Delpero JR; Lopez M; Aubert C
J Immunother (1991); 1992 Apr; 11(3):218-24. PubMed ID: 1515426
[TBL] [Abstract][Full Text] [Related]
99. Interleukin-2 therapy for refractory and relapsing lymphomas.
Tourani JM; Levy V; Briere J; Levy R; Franks C; Andrieu JM
Eur J Cancer; 1991; 27(12):1676-80. PubMed ID: 1782082
[TBL] [Abstract][Full Text] [Related]
100. Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: a phase II study.
Thatcher N; Dazzi H; Mellor M; Ghosh A; Carrington B; Johnson RJ; Loriaux EM; Craig RP
Br J Cancer; 1990 Apr; 61(4):618-21. PubMed ID: 2331447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
